Benitec Biopharma (BNTC) Expected to Announce Quarterly Earnings on Monday

Posted by Brenda Bartman on Sep 26th, 2026

Benitec Biopharma (NASDAQ:BNTC – Get Free Report) is projected to release its Q4 2026 results before the market opens on Monday, September 28th. Analysts expect the company to announce earnings of ($0.2686) per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2026 earning report page for the latest details on the call scheduled for Monday, September 14, 2026 at 4:00 PM ET.

Benitec Biopharma (NASDAQ:BNTC – Get Free Report) last posted its quarterly earnings results on Monday, September 14th. The biotechnology company reported ($0.26) earnings per share for the quarter, meeting the consensus estimate of ($0.26). On average, analysts expect Benitec Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Benitec Biopharma Trading Down 0.5%

Benitec Biopharma stock opened at $9.59 on Friday. Benitec Biopharma has a 1-year low of $9.26 and a 1-year high of $16.76. The firm has a market capitalization of $334.50 million, a price-to-earnings ratio of -9.79 and a beta of 0.27. The firm’s fifty day moving average price is $12.16 and its two-hundred day moving average price is $12.01.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Guggenheim lowered Benitec Biopharma from a “buy” rating to a “neutral” rating in a report on Wednesday, June 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Benitec Biopharma in a research report on Friday, July 17th. Wedbush lifted their target price on Benitec Biopharma from $16.00 to $17.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 15th. Citigroup reiterated a “market outperform” rating on shares of Benitec Biopharma in a research note on Tuesday, September 15th. Finally, Royal Bank Of Canada raised shares of Benitec Biopharma to an “outperform” rating in a report on Tuesday, September 15th. Seven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

Get Our Latest Stock Analysis on BNTC

About Benitec Biopharma

(Get Free Report)

Benitec Biopharma Inc (NASDAQ:BNTC) is a clinical-stage biotechnology company developing genetic medicines based on DNA-directed RNA interference (ddRNAi). The company’s technology is designed to enable long-lasting suppression of disease-causing genes by delivering genetic instructions that produce RNA interference molecules within targeted cells.

Benitec’s lead product candidate is BB-301, an investigational gene therapy being developed for oculopharyngeal muscular dystrophy type 1 (OPMD), a rare inherited disorder that can cause progressive weakness of the muscles involved in swallowing and eye movement.